Current screening methods of colorectal carcinoma are based on examination of occult bleeding in the stool, and further on endoscopic and irrigographical (barium enema) examinations. Population-based non-invasive screening method having high sensitivity and specificity is needed.
Detection of molecular alterations in colonocytes from the stool may be a promising new diagnostic tool for such screening. Determination of mutations in APC, K-ras, DCC, p53 genes and long DNA may serve for early detection of colorectal cancer from stool samples.
Multi-target DNA-assays employing all these markers suggest high sensitivity and specificity, unfortunately also expensiveness. Therefore finding a marker characteristic for all tumor cells would be desirable.
Nuclear faktor-kappaB (NF-ęB) could be such marker suitable for determination in colonocytes shed into the stool. Conclusion: Molecular testing of stool for early detection of colorectal cancer may be a promising screening method for this disease.
Large multicenter trials are required to validate results obtained from preliminary clinical studies.